Scarica l'app Stockscreener
6.44
0.17%
-0.04
Precedente Chiudi:
$6.48
Aprire:
$6.48
Volume 24 ore:
34,545
Relative Volume:
0.03
Capitalizzazione di mercato:
$707.51M
Reddito:
-
Utile/perdita netta:
$-167.48M
Rapporto P/E:
-3.3026
EPS:
-1.95
Flusso di cassa netto:
$-197.47M
1 W Prestazione:
+2.36%
1M Prestazione:
+2.69%
6M Prestazione:
-49.73%
1 anno Prestazione:
-53.22%
Intervallo 1D:
$6.37
$6.48
Intervallo di 1 settimana:
$6.20
$6.595
Portata 52W:
$6.08
$16.76
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
Nome
Day One Biopharmaceuticals Inc
Settore
Industria
Telefono
650 484-0899
Indirizzo
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
Confronta DAWN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
6.465 | 707.51M | 0 | -167.48M | -197.47M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.29 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
316.45 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
558.36 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
243.83 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-09 | Reiterato | Needham | Buy |
| 2024-08-01 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2024-04-24 | Reiterato | Needham | Buy |
| 2023-04-25 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-02-08 | Iniziato | CapitalOne | Overweight |
| 2023-02-03 | Iniziato | Oppenheimer | Perform |
| 2022-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-12-05 | Iniziato | Goldman | Buy |
| 2022-12-01 | Iniziato | BofA Securities | Buy |
Mostra tutto
Day One Biopharmaceuticals Inc Borsa (DAWN) Ultime notizie
Day 8 of Loss Streak for Day One Biopharmaceuticals Stock with -11% Return (vs. -49% YTD) [6/18/2025] - Trefis
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of “Buy” by Brokerages - Defense World
Pallas Capital Advisors LLC Takes Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Bank of America Corp DE Has $260,000 Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Where are the Opportunities in (DAWN) - news.stocktradersdaily.com
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Transcript : Day One Biopharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - MarketScreener
Day One Appoints Michael Vasconcelles As Head Of Research And Development - MarketScreener
Day One Biopharmaceuticals (DAWN) Welcomes New R&D Leader | DAWN Stock News - GuruFocus
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development - GlobeNewswire
Day One Taps ImmunoGen Executive to Lead R&D: 25-Year Oncology Expert Joins Cancer Drug Developer - Stock Titan
H.C. Wainwright Maintains Buy Rating on Day One Biopharmaceuticals (DAWN), Keeps PT - MSN
Ameriprise Financial Inc. Decreases Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Squarepoint Ops LLC Acquires New Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
JonesTrading Maintains Buy Rating on Day One Biopharmaceuticals (DAWN) Following Ojemda’s FDA Approval - Insider Monkey
Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301 - Seeking Alpha
Nuveen Asset Management LLC Lowers Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by Millennium Management LLC - Defense World
ProShare Advisors LLC Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 1,894 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Cetera Investment Advisers Has $400,000 Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
36,685 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Bought by BNP Paribas Financial Markets - Defense World
D. E. Shaw & Co. Inc. Increases Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of “Buy” from Brokerages - Defense World
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth - Yahoo Finance
Northern Trust Corp Grows Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day one Biopharmaceuticals officer sells $24,574 in stock By Investing.com - Investing.com Nigeria
Day one Biopharmaceuticals officer sells $24,574 in stock - Investing.com
Day One Biopharmaceuticals Executives Sell Shares to Cover Tax Liabilities - TradingView
Day one biopharmaceuticals highlights OJEMDA revenue growth and pipeline progress in Q1 2025 - MSN
Day One Biopharmaceuticals Insider Lowered Holding By 20% During Last Year - simplywall.st
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stake Decreased by Voya Investment Management LLC - Defense World
Transcript : Day One Biopharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Is Day One Biopharmaceuticals, Inc. (DAWN) the Best Low Priced Biotech Stock to Buy Now? - MSN
10 Best Low-Priced Biotech Stocks to Buy Now - Insider Monkey
Trend Tracker for (DAWN) - news.stocktradersdaily.com
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down – Here’s What Happened - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Research Analysts Issue Forecasts for DAWN Q2 Earnings - Defense World
Needham & Company LLC Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $27.00 - Defense World
Research Analysts Set Expectations for DAWN Q2 Earnings - Defense World
Is Day One Biopharmaceuticals, Inc. (DAWN) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey
Analysts Issue Forecasts for DAWN Q1 Earnings - Defense World
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up After Earnings Beat - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Mariner LLC - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 12-Month Low Following Analyst Downgrade - Defense World
Day One Biopharma’s Earnings Call Highlights Growth - TipRanks
Day One Biopharmaceuticals (DAWN) Target Price Adjusted to $26 | DAWN Stock News - GuruFocus
Needham Adjusts Price Target for DAWN to $27, Maintains Buy Rati - GuruFocus
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q1 2025 Earnings Call Transcript - Insider Monkey
Day One Biopharmaceuticals Inc Azioni (DAWN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Day One Biopharmaceuticals Inc Azioni (DAWN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Dubow Adam | GENERAL COUNSEL |
May 16 '25 |
Sale |
6.26 |
4,552 |
28,486 |
47,136 |
| York Charles N II | COO, CFO AND SECRETARY |
May 16 '25 |
Sale |
6.26 |
4,282 |
26,796 |
265,231 |
| Bender Jeremy | CHIEF EXECUTIVE OFFICER |
May 16 '25 |
Sale |
6.26 |
13,964 |
87,385 |
145,737 |
1.37%
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):